Workflow
肿瘤DNA甲基化测序技术
icon
Search documents
基准医疗UriFind助力尿路上皮癌术前无创诊断及术后复发监测
智通财经网· 2025-08-18 09:34
Group 1 - The 2025 Guangdong Urology Academic Conference and Bladder Cancer Academic Conference successfully concluded in Shenzhen, showcasing the innovative UriFind® product from Benchmark Medical [1] - The product demonstrated significant results in early screening and diagnosis of urothelial carcinoma, with a sensitivity of 89.74%, specificity of 92.46%, and accuracy of 91.47% based on a clinical study involving 1,172 samples [1] - UriFind® provides comprehensive assessment for bladder cancer, renal pelvis cancer, and ureteral cancer, particularly excelling in detecting early, small, residual, and recurrent bladder cancer [1] Group 2 - Benchmark Medical, a subsidiary of Kangsheng Global Medical Testing Group, focuses on cancer early diagnosis and screening using tumor DNA methylation sequencing technology [5] - The company has developed products targeting over 70% of high-incidence cancers, including lung cancer, breast cancer, digestive system cancers, and urinary system cancers, covering the entire process from early screening to monitoring and companion diagnosis [5] - Benchmark Medical has also established a big data and artificial intelligence platform centered on early screening, diagnosis, and treatment of lung cancer [5]